Metraipolis › archive › dc_10b60a75f2c7
A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy — Europe PMC PMID:42080357
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42080357
- DOI
- 10.1002/advs.202523024
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T18:55:21.504Z
- SHA-256 of the archived text
76b2fbccda85fb00343fd3790008de8c58f02d96f456303cbe6ffd64a09c1045- Stable URL of this page
https://metraipolis.com/documento/dc_10b60a75f2c7
How to cite
A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy — Europe PMC PMID:42080357 — Europe PMC (en), https://europepmc.org/article/MED/42080357 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_10b60a75f2c7 (Metraipolis archive dc_10b60a75f2c7, sha256 76b2fbccda85fb00343fd3790008de8c58f02d96f456303cbe6ffd64a09c1045)
BibTeX
@misc{dc10b60a75f2c7,
title = {A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy — Europe PMC PMID:42080357},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42080357},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_10b60a75f2c7; sha256 76b2fbccda85fb00343fd3790008de8c58f02d96f456303cbe6ffd64a09c1045},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42080357. Agents can read the archived copy with the MCP tool read_document.